Ocular medicine producer Graybug Vision sets targets for $92 million IPO
Graybug Vision Inc., which is developing medicines for ocular diseases, set price targets Monday for an IPO in which it hopes to raise up to $92 million.
The Redwood City company plans to sell 4.7 million shares on Thursday for between $15 and $17 each. It has also set aside 703,125 shares for its underwriters.
At the top of its range, Graybug would have a market cap of about $326 million. It plans to list of Nasdaq with the symbol of "GRAY."
Gra ybug Vision Inc. plans to use the cash to complete…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Cromwell Schubarth Source Type: news
More News: Biotechnology | Health Management